Cilostazol inhibits modified low-density lipoprotein uptake and foam cell formation in mouse peritoneal macrophages

Atherosclerosis

Volumn 204, Issue 2, 2009, Pages 405-411

  Okutsu, Reiko ^a   Yoshikawa, Tomohiro ^a   Nagasawa, Masakazu ^a   Hirose, Yoshimi ^a   Takase, Hiromichi ^a   Mitani, Kiminobu ^a   Okada, Keiko ^a   Miyakoda, Goro ^a   Yabuuchi, Youichi ^a  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Antiplatelet drug; Atherosclerosis; Cyclic AMP; Foam cells; Oxidized low density lipoprotein; Scavenger receptors

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CILOSTAZOL; LOW DENSITY LIPOPROTEIN; PHOSPHODIESTERASE III INHIBITOR; ROLIPRAM;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; FOAM CELL; LIPOPROTEIN BLOOD LEVEL; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD36; CARDIOVASCULAR AGENTS; CELLS, CULTURED; CHOLESTEROL ESTERS; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCYTOSIS; FOAM CELLS; LIPOPROTEINS, LDL; MACROPHAGES, PERITONEAL; MICE; PHOSPHODIESTERASE INHIBITORS; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; SCAVENGER RECEPTORS, CLASS A; TETRAZOLES;

EID: 67349112126     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.10.042     Document Type: Article

References (27)

1. Li A.C., and Glass C.K. The macrophage foam cell as a target for therapeutic intervention. Nat Med 8 (2002) 1235-1242
2. Glass C.K., and Witztum J.L. Atherosclerosis: the road ahead. Cell 104 (2001) 503-516
3. Lusis A.J. Atherosclerosis. Nature 407 (2000) 233-241
4. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
5. Moore K.J., and Freeman M.W. Scavenger receptors in atherosclerosis. Beyond lipid uptake. Arterioscler Thromb Vasc Biol 26 (2006) 1702-1711
6. Platt N., and Gordon S. Is the class A macrophage scavenger receptor (SR-A) multifunctional?-the mouse's tail. J Clin Invest 108 (2001) 649-654
7. Febbraio M., Hajjar D.P., and Silverstein R.L. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest 108 (2001) 785-791
8. Silverstein R.L., and Febbraio M. CD36 and atherosclerosis. Curr Opin Lipidol 11 (2000) 483-491
9. Kunjathoor V.V., Febbraio M., Podrez E.A., et al. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem 277 (2002) 49982-49988
10. Suzuki H., Kurihara Y., Takeya M., et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 386 (1997) 292-296
11. Febbraio M., Podrez E.A., Smith J.D., et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 105 (2000) 1049-1056
12. Kambayashi J., Liu Y., Sun B., Shakur Y., Yoshitake M., and Czerwiec F. Cilostazol as a unique antithrombotic agent. Curr Pharm Des 9 (2003) 2289-2302
13. Gotoh F., Tohgi H., Hirai S., et al. Cilostazol stroke prevention study: a placebo-controlled double blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 9 (2000) 147-157
14. Hashimoto A., Miyakoda G., Hirose Y., and Mori T. Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism. Atherosclerosis 189 (2006) 350-357
15. Kim K.Y., Shin H.K., Choi J.M., and Hong K.W. Inhibition of lipopolysaccharide-induced apoptosis by cilostazol in human umbilical vein endothelial cells. J Pharmacol Exp Ther 300 (2002) 709-715
16. Shin H.K., Kim Y.K., Kim K.Y., Lee J.H., and Hong K.W. Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation. Prevention by cilostazol. Circulation 109 (2004) 1022-1028
17. Otsuki M., Saito H., Xu X., et al. Cilostazol represses vascular cell adhesion molecule-1 gene transcription via inhibiting NF-κB binding to its recognition sequence. Atherosclerosis 158 (2001) 121-128
18. Park S.Y., Lee J.H., Kim C.D., et al. Cilostazol suppresses superoxide production and expression of adhesion molecules in human endothelial cells via mediation of cAMP-dependent protein kinase-mediated maxi-K channel activation. J Pharmacol Exp Ther 317 (2006) 1238-1245
19. DaRosa M.P., Boroni G.V., and Portal V.L. Cilostazol, a phosphodiesterase III inhibitor: future prospects for atherosclerosis. Arq Bras Cardiol 87 (2006) e221-e225
20. Takase H., Hashimoto A., Okutsu R., et al. Anti-atherosclerotic effect of cilostazol in apolipoprotein-E knockout mice. Drug Research 57 (2007) 185-191
21. Lee J.H., Oh G.T., Park S.Y., et al. Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-α formation in low-density lipoprotein receptor-null mice fed high cholesterol. J Pharmacol Exp Ther 313 (2005) 502-509
22. Daugherty A., Whitman S.C., Block A.E., and Rateri D.L. Polymorphism of class A scavenger receptors in C57BL/6 mice. J Lipid Res 41 (2000) 1568-1577
23. Voyta J.C., Via D.P., Butterfield C.E., and Zetter B.R. Identification and isolation of endothelial cells based on their increased uptake of acetylated-low density lipoprotein. J Cell Biol 99 (1984) 2034-2040
24. Lowry R.R. Ferric chloride spray detector for cholesterol and cholesteryl esters on thin-layer chromatograms. J Lipid Res 9 (1968) 397
25. Higashi T., Yamauchi A., and Shimada K. 2-Hydrazino-1-methylpyridine: a highly sensitive derivatization reagent for oxosteroids in liquid chromatography-electrospray ionization-mass spectrometry. J Chromatogr B 825 (2005) 214-222
26. Bennett B.L., Sasaki D.T., Murray B.W., et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 98 (2001) 13681-13686
27. Moriwaki H., Kume N., Sawamura T., et al. Ligand specificity of LOX-1, a novel endothelial receptor for oxidized low density lipoprotein. Arterioscler Thromb Vasc Biol 18 (1998) 1541-1547